Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tanezumab in Knee Osteoarthritis
NCT00830063Phase 3Completed
- Sponsor
- Pfizer
- Start
- May 2009
- Primary completion
- May 2010
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 3 trial of tanezumab in knee osteoarthritis (OA), sponsored by Pfizer. Started May 2009; status: completed.
02
Drugs
tanezumab
03
Conditions
knee osteoarthritis (OA)
Beyond the preview
Go deeper on NCT00830063.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00830063.